Cargando…
Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with...
Autores principales: | Zirngibl, Felix, Flemmig, Carina, Lang, Peter, Künkele, Annette, Eggert, Angelika, Schulte, Johannes H., Deubzer, Hedwig E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692027/ https://www.ncbi.nlm.nih.gov/pubmed/33126407 http://dx.doi.org/10.3390/children7110198 |
Ejemplares similares
-
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017) -
Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022) -
Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023) -
Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021) -
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)